Background: Cabazitaxel (CTX) is a second- generation taxane derivative, a class of potent anticancer drugs with very low water solubility. CTX is used in patients with resistant prostate cancer unresponsive to the first generation taxane, docetaxel. Currently marketed formulations of CTX contain high concentrations of surfactant and ethanol, which cause severe hypersensitivity reactions in patients.
Methods: In order to increase its solubility, two hemiester analogs; CTX-succinate and CTX-glutarate were synthesized and characterized. To improve the solubility of hemiesters even more, dextran as a biocompatible polymer was also conjugated to hemiester analogs. MTT assay was performed on MCF-7 cell line to evaluate the cytotoxicity effect of hemiesters and conjugates.
Results: Based on the results, hemiester analogs increased water solubility of the drug up to about 3 and 8 fold. Conjugation to dextran enhanced the CTX solubility to more than 1500 fold. These conjugates released the conjugated CTX in less than 24 hours in a pH dependent manner and showed proper hemocompatibility characteristics. The hemiesters had approximately similar cytotoxicity in comparison with CTX and the dextran conjugates showed higher cytotoxicity effect on MCF-7 cell line.
Keywords: Cabazitaxel, dextran conjugates, hemiesters, pH stability, water solubility, drugs.
Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions
Current Cancer Drug Targets Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Steroid 5α-Reductase Inhibitors
Mini-Reviews in Medicinal Chemistry Pre-Clinical and Clinical Aspects of Peptide-based Vaccine Against Human Solid Tumors
Recent Patents on Biotechnology Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Different Gene Therapy Strategies: A Overview for Prostate Cancer
Current Gene Therapy Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy In vitro Evaluation of Gadolinium-Silica Mesoporous Nanoparticles- Monoclonal Antibody: Potential Nanoprobe for Prostate Cancer Cell Imaging
Current Molecular Imaging (Discontinued) Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Current Pharmaceutical Design Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept
Current Cancer Drug Targets Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer
Current Genomics Flavonoids with Therapeutic Potential in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Methotrexate Loaded Chitosan Nanoparticles and in vitro Evaluation of the Potential in Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Highly Disordered Proteins in Prostate Cancer
Current Protein & Peptide Science Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued)